Literature DB >> 30227759

CDK9: a signaling hub for transcriptional control.

Curtis W Bacon1, Iván D'Orso2.   

Abstract

Cyclin-dependent kinase 9 (CDK9) is critical for RNA Polymerase II (Pol II) transcription initiation, elongation, and termination in several key biological processes including development, differentiation, and cell fate responses. A broad range of diseases are characterized by CDK9 malfunction, illustrating its importance in maintaining transcriptional homeostasis in basal- and signal-regulated conditions. Here we provide a historical recount of CDK9 discovery and the current models suggesting CDK9 is a central hub necessary for proper execution of different steps in the transcription cycle. Finally, we discuss the current therapeutic strategies to treat CDK9 malfunction in several disease states. Abbreviations: CDK: Cyclin-dependent kinase; Pol II: RNA Polymerase II; PIC: Pre-initiation Complex; TFIIH: Transcription Factor-II H; snoRNA: small nucleolar RNA; CycT: CyclinT1/T2; P-TEFb: Positive Transcription Elongation Factor Complex; snRNP: small nuclear ribonucleo-protein; HEXIM: Hexamethylene Bis-acetamide-inducible Protein 1/2; LARP7: La-related Protein 7; MePCE: Methylphosphate Capping Enzyme; HIV: human immunodeficiency virus; TAT: trans-activator of transcription; TAR: Trans-activation response element; Hsp70: Heat Shock Protein 70; Hsp90/Cdc37: Hsp90- Hsp90 co-chaperone Cdc37; DSIF: DRB Sensitivity Inducing Factor; NELF: Negative Elongation Factor; CPSF: cleavage and polyadenylation-specific factor; CSTF: cleavage-stimulatory factor; eRNA: enhancer RNA; BRD4: Bromodomain-containing protein 4; JMJD6: Jumonji C-domain-containing protein 6; SEC: Super Elongation Complex; ELL: eleven-nineteen Lys-rich leukemia; ENL: eleven-nineteen leukemia; MLL: mixed lineage leukemia; BEC: BRD4-containing Elongation Complex; SEC-L2/L3: SEC-like complexes; KAP1: Kruppel-associated box-protein 1; KEC: KAP1-7SK Elongation Complex; DRB: Dichloro-1-ß-D-Ribofuranosylbenzimidazole; H2Bub1: H2B mono-ubiquitination; KM: KM05382; PP1: Protein Phosphatase 1; CDK9i: CDK9 inhibitor; SHAPE: Selective 2'-hydroxyl acylation analyzed by primer extension; TE: Typical enhancer; SE : Super enhancer.

Entities:  

Keywords:  7SK; CDK9; Cancer; Disease; Elongation; Enhancer; HIV; P-TEFb; Pausing; RNA polymerase II; Transcription

Mesh:

Substances:

Year:  2018        PMID: 30227759      PMCID: PMC6602564          DOI: 10.1080/21541264.2018.1523668

Source DB:  PubMed          Journal:  Transcription        ISSN: 2154-1272


  44 in total

1.  Transcriptional CDKs in the spotlight.

Authors:  Joaquin M Espinosa
Journal:  Transcription       Date:  2019-04

Review 2.  Causes and consequences of RNA polymerase II stalling during transcript elongation.

Authors:  Melvin Noe Gonzalez; Daniel Blears; Jesper Q Svejstrup
Journal:  Nat Rev Mol Cell Biol       Date:  2020-11-18       Impact factor: 94.444

3.  Stabilize and connect: the role of LARP7 in nuclear non-coding RNA metabolism.

Authors:  Daniele Hasler; Gunter Meister; Utz Fischer
Journal:  RNA Biol       Date:  2020-06-03       Impact factor: 4.652

4.  Efficacy of combined CDK9/BET inhibition in preclinical models of MLL-rearranged acute leukemia.

Authors:  Hannah McCalmont; Ka Leung Li; Luke Jones; John Toubia; Sarah C Bray; Debora A Casolari; Chelsea Mayoh; Saumya E Samaraweera; Ian D Lewis; Rab K Prinjha; Nicholas Smithers; Shudong Wang; Richard B Lock; Richard J D'Andrea
Journal:  Blood Adv       Date:  2020-01-28

Review 5.  Dissecting the Pol II transcription cycle and derailing cancer with CDK inhibitors.

Authors:  Pabitra K Parua; Robert P Fisher
Journal:  Nat Chem Biol       Date:  2020-06-22       Impact factor: 15.040

6.  Flavopiridol Mitigates the Progression of Monocrotaline-Induced Pulmonary Hypertension in Rats by Targeting Cyclin-Dependent Kinase 9.

Authors:  Qi Jia; Zhiqiang Hu; Nannan Song; Weike Mao
Journal:  Cardiovasc Drugs Ther       Date:  2022-01-28       Impact factor: 3.727

Review 7.  CDK inhibitors in cancer therapy, an overview of recent development.

Authors:  Mengna Zhang; Lingxian Zhang; Ruoxuan Hei; Xiao Li; Haonan Cai; Xuan Wu; Qiping Zheng; Cheguo Cai
Journal:  Am J Cancer Res       Date:  2021-05-15       Impact factor: 6.166

Review 8.  Cyclin-Dependent Kinase Inhibitors in Hematological Malignancies-Current Understanding, (Pre-)Clinical Application and Promising Approaches.

Authors:  Anna Richter; Nina Schoenwaelder; Sina Sender; Christian Junghanss; Claudia Maletzki
Journal:  Cancers (Basel)       Date:  2021-05-20       Impact factor: 6.639

Review 9.  CDK9 keeps RNA polymerase II on track.

Authors:  Sylvain Egloff
Journal:  Cell Mol Life Sci       Date:  2021-06-19       Impact factor: 9.261

10.  Human prefoldin modulates co-transcriptional pre-mRNA splicing.

Authors:  Laura Payán-Bravo; Sara Fontalva; Xenia Peñate; Ildefonso Cases; José Antonio Guerrero-Martínez; Yerma Pareja-Sánchez; Yosu Odriozola-Gil; Esther Lara; Silvia Jimeno-González; Carles Suñé; Mari Cruz Muñoz-Centeno; José C Reyes; Sebastián Chávez
Journal:  Nucleic Acids Res       Date:  2021-06-21       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.